日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response

MAPK通路突变出现在对IDH1抑制剂耐药的胆管癌中,并减弱IFN反应

Wan, Jinkai; Saatcioglu, Hatice Duygu; Ellis, Haley; Aguado-Fraile, Elia; Xu, Qin; Kondo, Hiroshi; Manguso, Robert T; Gritti, Ilaria; Norden, Bryanna L; Noble, Carolina; Corcoran, Ryan B; Lubner, Sam J; Javle, Milind; Abou-Alfa, Ghassan K; Cleary, James M; Kelley, Robin K; Borad, Mitesh J; Macarulla, Teresa; Oh, Do Youn; Daigle, Scott; Gliser, Camelia; Pandya, Susan; Choe, Sung; Tron, Adriana E; Bardeesy, Nabeel

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma

对 ivosidenib 与安慰剂治疗 mIDH1 胆管癌患者的 III 期 ClarIDHy 研究数据进行定量获益风险评估

Valle, J W; Abou-Alfa, G K; Kelley, R K; Lowery, M A; Shroff, R T; Bian, Y; Saint-Hilary, G; Liu, H; Teng, Z; Hua, Z; Gliser, C; Vogel, A; Javle, M M

Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study

ivosidenib在晚期IDH1突变型胆管癌中的药代动力学/药效学:来自III期ClarIDHy研究的结果

Fan, Bin; Abou-Alfa, Ghassan K; Zhu, Andrew X; Pandya, Shuchi S; Jia, Hongxia; Yin, Feng; Gliser, Camelia; Hua, Zhaowei; Hossain, Mohammad; Yang, Hua

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

Ivosidenib治疗IDH1突变晚期胆管癌患者的最终总生存期疗效结果:3期随机临床试验ClarIDHy

Zhu, Andrew X; Macarulla, Teresa; Javle, Milind M; Kelley, R Kate; Lubner, Sam J; Adeva, Jorge; Cleary, James M; Catenacci, Daniel V T; Borad, Mitesh J; Bridgewater, John A; Harris, William P; Murphy, Adrian G; Oh, Do-Youn; Whisenant, Jonathan R; Lowery, Maeve A; Goyal, Lipika; Shroff, Rachna T; El-Khoueiry, Anthony B; Chamberlain, Christina X; Aguado-Fraile, Elia; Choe, Sung; Wu, Bin; Liu, Hua; Gliser, Camelia; Pandya, Shuchi S; Valle, Juan W; Abou-Alfa, Ghassan K

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant- IDH1 cholangiocarcinoma

ivosidenib 诱导的分子和形态变化与突变型 IDH1 胆管癌的疗效相关

Elia Aguado-Fraile, Ania Tassinari, Yuko Ishii, Carlie Sigel, Maeve A Lowery, Lipika Goyal, Camelia Gliser, Liewen Jiang, Shuchi S Pandya, Bin Wu, Nabeel Bardeesy, Sung Choe, Vikram Deshpande

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

突变型IDH1抑制剂Ivosidenib的I期研究:在晚期软骨肉瘤患者中的安全性和临床活性

Tap, William D; Villalobos, Victor M; Cote, Gregory M; Burris, Howard; Janku, Filip; Mir, Olivier; Beeram, Murali; Wagner, Andrew J; Jiang, Liewen; Wu, Bin; Choe, Sung; Yen, Katharine; Gliser, Camelia; Fan, Bin; Agresta, Sam; Pandya, Shuchi S; Trent, Jonathan C

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ivosidenib治疗IDH1突变型化疗难治性胆管癌(ClarIDHy):一项多中心、随机、双盲、安慰剂对照的3期研究

Abou-Alfa, Ghassan K; Macarulla, Teresa; Javle, Milind M; Kelley, Robin K; Lubner, Sam J; Adeva, Jorge; Cleary, James M; Catenacci, Daniel V; Borad, Mitesh J; Bridgewater, John; Harris, William P; Murphy, Adrian G; Oh, Do-Youn; Whisenant, Jonathan; Lowery, Maeve A; Goyal, Lipika; Shroff, Rachna T; El-Khoueiry, Anthony B; Fan, Bin; Wu, Bin; Chamberlain, Christina X; Jiang, Liewen; Gliser, Camelia; Pandya, Shuchi S; Valle, Juan W; Zhu, Andrew X

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

ivosidenib(一种口服的、靶向突变型IDH1的抑制剂)在晚期实体瘤患者中的临床药代动力学和药效学研究

Fan, Bin; Mellinghoff, Ingo K; Wen, Patrick Y; Lowery, Maeve A; Goyal, Lipika; Tap, William D; Pandya, Shuchi S; Manyak, Erika; Jiang, Liewen; Liu, Guowen; Nimkar, Tara; Gliser, Camelia; Prahl Judge, Molly; Agresta, Sam; Yang, Hua; Dai, David

Urinary Paraben Concentrations and Its Association with Serum Triglyceride Concentrations in 2013–2014 NHANES Participants (P08-120-19)

2013-2014 年 NHANES 参与者尿液中对羟基苯甲酸酯浓度及其与血清甘油三酯浓度的关系 (P08-120-19)

Lowery, Maeve A; Burris, Howard A 3rd; Janku, Filip; Shroff, Rachna T; Cleary, James M; Azad, Nilofer S; Goyal, Lipika; Maher, Elizabeth A; Gore, Lia; Hollebecque, Antoine; Beeram, Muralidhar; Trent, Jonathan C; Jiang, Liewen; Fan, Bin; Aguado-Fraile, Elia; Choe, Sung; Wu, Bin; Gliser, Camelia; Agresta, Samuel V; Pandya, Shuchi S; Zhu, Andrew X; Abou-Alfa, Ghassan K; Mucci, A; Giordano, GM; Galderisi, S; Ly, Annie; Uniyal, Apurva; Church, Terry; Larkin, Trisha; Blatt, Jason; Gururangan, Sridharan; Hamamoto, Ryuji; Pazos, Rebecca; Palacios, Cristina; Campa, Adriana

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

联合靶向治疗可破坏 IDH2 和 TET2 突变型急性髓系白血病中的异常致癌信号传导并逆转表观遗传功能障碍

Shih Alan H, Meydan Cem, Shank Kaitlyn, Garrett-Bakelman Francine E, Ward Patrick S, Intlekofer Andrew M, Nazir Abbas, Stein Eytan M, Knapp Kristina, Glass Jacob, Travins Jeremy, Straley Kim, Gliser Camelia, Mason Christopher E, Yen Katharine, Thompson Craig B, Melnick Ari, Levine Ross L